illumina is a biotechnology company that specializes in genetic sequencing and analysis. The company was founded in 1998 and is headquartered in San Diego, California. Illumina’s primary focus is on developing innovative technologies and solutions for genetic analysis that enable researchers to study complex biological systems and diseases in unprecedented detail.
Illumina’s flagship product is the sequencing platform, widely used in genomic research and clinical applications. The platform is based on a proprietary technology known as reversible terminator sequencing, which allows for highly accurate and efficient sequencing of DNA and RNA molecules. Illumina’s sequencing instruments can generate massive amounts of sequencing data in a short time, enabling researchers to sequence entire genomes, transcriptomes, and epigenomes at a fraction of the cost and time required by previous technologies.
illumina Medical Devices
1 – MiSeq Dx System
MiSeq Dx System is a next-generation sequencing (NGS) platform designed for clinical diagnostic applications. It is capable of generating high-quality, accurate, and reliable sequencing data, making it an ideal choice for a wide range of clinical applications, such as infectious disease diagnosis, cancer profiling, and genetic testing. It uses Illumina’s proprietary sequencing-by-synthesis (SBS) technology, which enables it to sequence millions of DNA molecules in parallel.
One of the key features of the MiSeq Dx System is its flexibility. It can handle a variety of sample types, including DNA, RNA, and microbial samples. It can also accommodate different sequencing applications, such as whole-genome sequencing, targeted sequencing, and metagenomic sequencing. This makes it a versatile tool for a range of clinical applications.
2 – VeriSeq NIPT
VeriSeq NIPT (Non-Invasive Prenatal Testing) Solution is a high-throughput sequencing technology designed to detect fetal chromosomal abnormalities using a maternal blood sample. This solution uses Next-Generation Sequencing (NGS) technology to analyze cell-free DNA (cfDNA) from the maternal bloodstream to detect and quantify the relative amounts of chromosomal material from the fetus.
VeriSeq NIPT Solution can detect the most common chromosomal abnormalities, including trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), and trisomy 13 (Patau syndrome). It can also detect sex chromosome aneuploidies, such as Turner syndrome (monosomy X) and Klinefelter syndrome (XXY).
The VeriSeq NIPT Solution is a comprehensive and accurate solution that can detect fetal chromosomal abnormalities with a high degree of sensitivity and specificity. It uses a unique molecular barcoding approach that reduces the risk of sequencing errors and allows for the accurate detection of fetal chromosomal abnormalities.
Medical Device Lists
- MiSeq Dx System
- VeriSeq NIPT